Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von GraveDigger 

CVS Health Corp. diskutieren

CVS Health Corp.

WKN: 859034 / Symbol: CVS / Name: CVS Health / Aktie / Lebensmittel- & Medikamentenhandel / Large Cap /

67,30 €
3,27 %

Einschätzung Buy
Rendite (%) 25,08 %
Kursziel 65,63
Veränderung
Endet am 07.11.25

CVS Health Co. (NYSE: CVS) had its price target lowered by analysts at Barclays PLC from $75.00 to $71.00. They now have an "overweight" rating on the stock.
Ratings data for CVS provided by MarketBeat

Einschätzung Buy
Rendite (%) 31,96 %
Kursziel 54,97
Veränderung
Endet am 15.11.25

CVS Health Co. (NYSE: CVS) had its price target lowered by analysts at Royal Bank of Canada from $68.00 to $58.00. They now have an "outperform" rating on the stock.
Ratings data for CVS provided by MarketBeat

Einschätzung Buy
Rendite (%) 30,28 %
Kursziel 62,44
Veränderung
Endet am 18.11.25

CVS Health Co. (NYSE: CVS) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $66.00 price target on the stock, up previously from $60.00.
Ratings data for CVS provided by MarketBeat

Einschätzung Buy
Rendite (%) 23,19 %
Kursziel 63,62
Veränderung
Endet am 20.11.25

CVS Health Co. (NYSE: CVS) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $67.00 price target on the stock, down previously from $76.00.
Ratings data for CVS provided by MarketBeat

Einschätzung Buy
Rendite (%) 18,81 %
Kursziel 60,90
Veränderung
Endet am 25.11.25

CVS Health Co. (NYSE: CVS) had its price target lowered by analysts at Piper Sandler from $72.00 to $64.00. They now have an "overweight" rating on the stock.
Ratings data for CVS provided by MarketBeat

Einschätzung Buy
Rendite (%) 19,23 %
Kursziel 76,19
Veränderung
Endet am 25.11.25

CVS Health Co. (NYSE: CVS) had its price target raised by analysts at TD Cowen from $73.00 to $80.00. They now have a "buy" rating on the stock.
Ratings data for CVS provided by MarketBeat

Einschätzung Buy
Rendite (%) 14,65 %
Kursziel 62,71
Veränderung
Endet am 03.12.25

CVS Health Co. (NYSE: CVS) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "buy" rating. They now have a $66.00 price target on the stock.
Ratings data for CVS provided by MarketBeat

Einschätzung Buy
Rendite (%) 52,16 %
Kursziel 57,57
Veränderung
Endet am 06.01.26

CVS Health Co. (NYSE: CVS) had its price target lowered by analysts at Truist Financial Co. from $67.00 to $60.00. They now have a "buy" rating on the stock.
Ratings data for CVS provided by MarketBeat

Einschätzung Buy
Rendite (%) 26,20 %
Kursziel 61,91
Veränderung
Endet am 27.01.26

CVS Health Co. (NYSE: CVS) had its price target raised by analysts at Evercore ISI from $60.00 to $65.00. They now have an "outperform" rating on the stock.
Ratings data for CVS provided by MarketBeat

Einschätzung Buy
Rendite (%) 26,05 %
Kursziel 67,53
Veränderung
Endet am 11.02.26

CVS Health Co. (NYSE: CVS) had its price target raised by analysts at Wolfe Research from 67.00 to 70.00. They now have an "overweight" rating on the stock.
Ratings data for CVS provided by MarketBeat

CVS Health Co. (NYSE: CVS) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating.
Ratings data for CVS provided by MarketBeat

Einschätzung Buy
Rendite (%) 10,15 %
Kursziel 73,11
Veränderung
Endet am 13.02.26

CVS Health Co. (NYSE: CVS) had its price target raised by analysts at Truist Financial Co. from $60.00 to $76.00. They now have a "buy" rating on the stock.
Ratings data for CVS provided by MarketBeat

Einschätzung Buy
Rendite (%) 10,15 %
Kursziel 70,23
Veränderung
Endet am 13.02.26

CVS Health Co. (NYSE: CVS) had its price target raised by analysts at Barclays PLC from $71.00 to $73.00. They now have an "overweight" rating on the stock.
Ratings data for CVS provided by MarketBeat

Einschätzung Buy
Rendite (%) 7,27 %
Kursziel 69,99
Veränderung
Endet am 13.02.26

CVS Health Co. (NYSE: CVS) had its price target raised by analysts at Wells Fargo & Company from $68.00 to $73.00. They now have an "overweight" rating on the stock.
Ratings data for CVS provided by MarketBeat

CVS Health Co. (NYSE: CVS) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
Ratings data for CVS provided by MarketBeat

Einschätzung Buy
Rendite (%) 7,46 %
Kursziel 77,44
Veränderung
Endet am 18.02.26

CVS Health Co. (NYSE: CVS) had its price target raised by analysts at JPMorgan Chase & Co. from $80.00 to $81.00. They now have an "overweight" rating on the stock.
Ratings data for CVS provided by MarketBeat

Einschätzung Buy
Rendite (%) 7,65 %
Kursziel 68,19
Veränderung
Endet am 21.03.26

CVS Health Co. (NYSE: CVS) had its price target raised by analysts at Piper Sandler from $72.00 to $74.00. They now have an "overweight" rating on the stock.
Ratings data for CVS provided by MarketBeat

Einschätzung Buy
Rendite (%) 12,41 %
Kursziel 68,89
Veränderung
Endet am 09.04.26

CVS Health Co. (NYSE: CVS) had its price target raised by analysts at Mizuho from $70.00 to $76.00. They now have an "outperform" rating on the stock.
Ratings data for CVS provided by MarketBeat

Einschätzung Buy
Rendite (%) 11,53 %
Kursziel 72,69
Veränderung
Endet am 11.04.26

CVS Health Co. (NYSE: CVS) had its price target raised by analysts at Truist Financial Co. from $76.00 to $82.00. They now have a "buy" rating on the stock.
Ratings data for CVS provided by MarketBeat

CVS Health Co. (NYSE: CVS) had its "overweight" rating re-affirmed by analysts at Morgan Stanley.
Ratings data for CVS provided by MarketBeat